Indeed, rhCD137L-MSNs optimized for maximal encapsulated efficiency (20 μg rhCD137L + 1.6x1010 MSNs) failed to promote effector T cell-mediated killing of the CD137-expressing NPC cell line (C666-CD137) and its CD137-deficient control cells (C666) (Figure 2D). This evidence concerns the gene TNFRSF9 and nasopharyngeal carcinoma.